With an FDA de­ci­sion loom­ing, Dy­navax is shop­ping a deal on Hep­lisav — re­port

Late Fri­day Reuters re­port­ed that Dy­navax Tech­nolo­gies $DVAX was shop­ping its he­pati­tis B vac­cine Hep­lisav in the wake of a pos­i­tive FDA pan­el re­view and a shot at a near-term FDA ap­proval.

Quot­ing sources, the wire ser­vice re­port­ed that Dy­navax is en­gaged in a strate­gic re­view, with a chance of bag­ging a sale or li­cens­ing pact that could bring in a sub­stan­tial amount of cash. Reuters added that there is no guar­an­tee of a deal, as Dy­navax re­it­er­at­ed that it’s plan­ning a mar­ket launch for 2018. A com­pa­ny spokesper­son added: “We con­tin­ue to eval­u­ate any in­ter­est from po­ten­tial part­ners as part of our long-term strate­gic plan­ning.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.